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Abstract
Background: Currently, Atypical Teratoid Rhabdoid Tumor (AT/RT) constitutes one of the most difficult to treat
malignancies in pediatrics. Hence, new knowledge of potential targets for therapeutics and the development of
novel treatment approaches are urgently needed. We have evaluated the presence of cytokine pathways and the
effects of two clinically available multi-tyrosine kinase inhibitors for cytotoxicity, target modulation and drug
combinability against AT/RT cell lines.
Results: AT/RT cell lines expressed measurable quantities of VEGF, FGF, PDGF and SDF-1, although the absolute
amounts varied between the cell lines. The targeted receptor tyrosine kinase inhibitor sorafenib inhibited the key
signaling molecule Erk, which was activated following the addition of own conditioned media, suggesting the
existence of autocrine/paracrine growth stimulatory pathways. The multi-tyrosine kinase inhibitors sorafenib and
sunitinib also showed significant growth inhibition of AT/RT cells and their activity was enhanced by combination
with the topoisomerase inhibitor, irinotecan. The loss of cytoplasmic NF-kappa-B in response to irinotecan was
diminished by sorafenib, providing evidence for a possible benefit for this drug combination.
Conclusions: In addition to previously described involvement of insulin like growth factor (IGF) family of cytokines,
a multitude of other growth factors may contribute to the growth and survival of AT/RT cells. However, consistent
with the heterogeneous nature of this tumor, quantitative and qualitative differences may exist among different
tumor samples. Multi-tyrosine kinase inhibitors appear to have effective antitumor activity against all cell lines
studied. In addition, the target modulation studies and drug combinability data provide the groundwork for
additional studies and support the evaluation of these agents in future treatment protocols.
Background
Atypical Teratoid Rhabdoid Tumor of the central nervous
system (CNS AT/RT) is a highly malignant neoplasm of
infants and young children. A biallelic inactivation of the
hSnf5/Ini1 gene located in 22q11.2 is a characteristic mole-
cular defect in these tumors [1-4]. Murine knock-out mod-
els have confirmed that hSnf5/Ini1 is a tumor-suppressor
gene [5], but the details of its exact role in the initiation
and growth of the AT/RT are still being investigated. To
date, studies showing INI1 interaction with key signaling
molecules suggest its potential to modify the response to
factors that mediate cell growth and differentiation pro-
grams [6-8]. There is emerging evidence for the existence
of autocrine and/or paracrine growth factor signaling path-
ways in these cells. Previously, we were able to maintain
disseminated AT/RT cells in culture by the addition of
autologous CSF to culture medium [9]. Agents that inhibit
IGF-IR activity have been shown to diminish tumor cell
growth and targeting of IGF-IR expression with antisense
oligonucleotides resulted in increased apoptosis and sensi-
tivity to a number of chemotherapeutic agents [10].
Furthermore, Arcaro and colleagues have shown evidence
for autocrine signaling by insulin and its receptor (IR) in
AT/RT cells, which involves the PI3K/Akt pathway [11].
These findings suggest that abnormally regulated cytokine
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effective targets for therapeutics in AT/RT.
Ultra structurally, AT/RT often presents as a polymor-
phous tumor with overlapping morphologic features con-
sisting of primitive neuroectodermal tumor (PNET),
mesenchymal, rhabdoid and epithelial components. This
phenotypic heterogeneity is likely to be aided by multi-
level cross stimulation of growth and survival pathways
and signaling molecules. As such, a single-targeted agent
may not be the optimal choice, as these agents may permit
the development of salvage or escape mechanisms. How-
ever, by virtue of their ability to interfere with a diverse
array of signaling molecules, including cytokine receptor
kinases, multi-targeted inhibitors may provide a therapeu-
tic advantage in the treatment of AT/RT. In the recent
past, tyrosine kinase inhibitors with multiple targets have
been found to have clinically achievable activity and accep-
table tolerability in studies against heterogeneous malig-
nancies [12]. In this study, we have evaluated two such
agents, sunitinib and sorafenib, for in vitro activity and
drug combinability against three AT/RT cell lines.
Results
Cytokine expression by AT/RT cells
Quantitative evaluation of the cytokines found in the cul-
ture supernatants of the three AT/RT cell lines was per-
formed by multiplex assay. Data presented in Table 1
shows significant presence of six of the 65 cytokines exam-
ined. However, with the exception of VEGF, other cyto-
kines showed quantitative variations between the cell lines.
F o re x a m p l e ,i nc o m p a r i s o nt oB T 1 2a n dK C C F 1c e l l s ,
BT16 cells did not express measurable levels of IL-8 and
M C P - 1 ,a n de x p r e s s e do n l yav e r yl o wl e v e lo fS D F - 1 .
Although BT12 supernatants contained higher quantities
of all other cytokines, the level of FGF(b) was measurably
lower in this sample, indicating the potential heterogeneity
in the presence of different cytokines in the tumor micro-
environment.
Sensitivity of AT/RT cell lines to multi-targeted tyrosine
kinase inhibitors and irinotecan
The presence of a multitude of cytokines in the culture
supernatants of the AT/RT cell lines indicated the poten-
tial for autocrine or paracrine growth sustaining processes
utilizing these molecules. Therefore, we wanted to investi-
gate the effects of agents that have been shown to interfere
with the activity of such receptor pathways. Sorafenib and
sunitinib have been shown to inhibit the activity of a num-
ber of cytokine receptors, including vascular endothelial
growth factor receptor (VEGFR), platelet-derived growth
factor receptor (PDGFR), stem cell factor receptor (c-Kit)
and FMS-like tyrosine kinase-3 (Flt-3) [13,14]. In the next
set of experiments, the three AT/RT cell lines were evalu-
ated for sensitivity to sorafenib and sunitinib by in vitro
cytotoxicity assays. Figures 1A and 1B show the dose
dependent inhibition of AT/RT cell growth by these
agents. From these data, IC50 values were calculated and
presented in Table 2. IC50 values for each cell line ranged
from 2.8 to 3.6 µM for sorafenib and 3.2 to 3.7 µM for
sunitinib. As a means to further support the targeted inhi-
bition of receptor pathways by sorafenib and sunitinib, the
expression of proteins targeted by these inhibitors was
determined by Western blot analysis. It was found that all
three AT/RT cell lines expressed receptor tyrosine kinases
c-Kit, PDGF-Rb, VEGFR2 and Flt-3, as well as the intra-
cellular targets of sorafenib, c-Raf and p38a (Figure 2).
Synergistic activity of irinotecan with sorafenib and
sunitinib
Previous studies have indicated the potential activity of the
new generation topoisomerase I inhibitor irinotecan
against brain tumors and its ability to increase the activity
of agents that block VEGF activity [15]. To deduce the
role of irinotecan in potential combination therapies, we
first analyzed its activity as a single agent. Figure 3 shows
the cytotoxic effects of irinotecan against the three AT/RT
cell lines. The IC50 values (Table 2) ranged from 2.0 to
6.7 μM, with BT12 cell line exhibiting a significantly lower
IC50 value of 2 μM compared to other two cell lines. We
also tested the activity of the active metabolite of irinote-
can, SN-38 against the three AT/RT cell lines. The IC50
values (Table 2) ranged from 0.03 to 4.6 μM, with KCCF1
exhibiting a significantly higher IC50 value compared to
the other two cell lines. Next, we evaluated the drug com-
binability of irinotecan with sorafenib and sunitinib. The
ability of a fixed concentration of irinotecan (IC25)t o
reduce the IC50 values in serially diluted sorafenib and
sunitinib was evaluated by in vitro cytotoxicity assays and
combination indices (CI) were calculated according to the
method of Chou and Talalay [16]. Table 3 shows the
respective CI calculations. Combination index values less
than 1 (CI < 1) indicates synergy between two agents.
Modulation of intracellular signaling molecules by
sorafenib
Our initial set of experiments involved the screening of
changes in the activation status of signaling molecules
in response to treatment with sorafenib in AT/RT cells.
Table 1 Quantitative analysis of cytokines present in the
spent culture supernatants of AT/RT cell lines
Cytokine (rg/ml) FGF(b) IL-8 MCP-1 PDGF-AA VEGF SDF-1
Media Control UD UD UD UD 16.26 UD
BT 12 Supernatant 14.93 144.7 63.38 157.76 226.67 228.28
BT 16 Supernatant 82.45 UD UD 197.06 261.04 4.74
KCCF1 Supernatant 40.35 10.18 UD 43.35 124.57 190.17
UD - undetectable
Jayanthan et al. Cancer Cell International 2011, 11:44
http://www.cancerci.com/content/11/1/44
Page 2 of 11Exponentially growing cells were treated with 10 µM of
sorafenib, or appropriate vehicle control, and cell lysates
were analyzed by Western blots as described in materi-
als and methods. Data presented in Figure 4A shows
that, in most cases, sorafenib decreased the levels of
multiple signaling components in AT/RT cells Signifi-
cant loss of phosphorylated cell growth regulators was
seen in all AT/RT cells although variations were seen
among the different cell lines; Erk1/2 (BT12, KCCF1),
Figure 1 Sorafenib and sunitinib induce cell growth inhibition in AT/RT cell lines in vitro. Triplicate cultures of three AT/RT cell lines were
incubated with increasing concentrations of sorafenib (A) or sunitinib (B). Appropriate dilutions of DMSO were also included as vehicle control.
After four days in culture, cell viability was measured and plotted as a percentage of cell survival compared to equivalent vehicle control. Bars
indicate SD. Data presented above are representative of five separate experiments. IC50 values calculated from these data are given in Table 2.
Table 2 In vitro cytotoxicity of sorafenib, sunitinib,
irinotecan and SN-38 against three AT/RT cell lines
Inhibitor, IC50 (μM) BT 12 BT 16 KCCF1
Sorafenib 3.3 2.8 3.6
Sunitinib 3.2 3.2 3.7
Irinotecan 2.0 4.1 6.7
SN-38 0.09 0.03 4.6
IC50 - half maximal inhibitory concentration
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KCCF1). Loss of the cell survival molecule Mcl-1, how-
ever, was found in all three cell lines studied.
The addition of conditioned medium to cells that are
serum starved provides an experimental model to study
the autocrine/paracrine pathways mediated by secreted
cytokines. Agents that block such activation pathways may
contribute to ultimate growth inhibitory activities and pro-
vide a rationale for investigating receptor tyrosine kinase
inhibitors as targeted therapeutics. In the next set of
experiment we demonstrate that indeed the conditioned
media from AT/RT cells induce Erk phosphorylation,
which has been shown to be one of the downstream
targets of sorafenib activity (Figure 4B).
Previous studies have suggested that the activation of
NF-kappa-B (NF-B) in response to chemotherapeutic
agents, including irinotecan may relate to the generation
of resistance in cancer cells [17,18]. To further evaluate
the input of MTK inhibition in this process, we evaluated
the effect on NF-B in response to irinotecan as a single
agent and then in combination with sorafenib. Using
BT12 cells, we examined the presence of cytoplasmic
NF-B by indirect immunofluorescence. Cells receiving
sorafenib, irinotecan or the combination were fixed and
stained with antibodies to NF-B. The slides were visua-
lized under a fluorescent microscope and random fields
were photographed. Representative photographs in Fig-
ure 5A show that the cytoplasmic staining of NF-Bi s
unchanged in sorafenib treated cells compared to control
cells, but there is a significant reduction in such staining
when the cells were treated with irinotecan. However,
this loss is reduced by combination with sorafenib. As
activated NK-B translocates from cytoplasm during the
activation process, this indicates that irinotecan and sora-
fenib combination leads to potentially reduced transloca-
tion of NF-Bc o m p a r e dt oi r i n o t e c a na l o n e .T of u r t h e r
Figure 2 Expression of targets of sorafenib and sunitinib in AT/RT cell lines. Using Western blot analysis, it was determined that AT/RT cell
lines express receptor tyrosine kinase targets of sorafenib and sunitinib: c-Kit, PDGF-Rb, VEGFR2 and Flt-3. In addition, these cell lines express
intracellular targets of sorafenib: c-Raf and p38a.
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ted with either irinotecan alone or the irinotecan and sor-
afenib combination were evaluated by Western blot
analysis. Results presented in Figure 5B show that NF-B
p65 detected with irinotecan alone is significantly less
compared to levels detected when the cells received
added sorafenib. This suggests that sorafenib may be able
to reduce the translocation and hence the activation on
NF-B that follows irinotecan treatment. In addition,
compared to treatment with sorafenib or irinotecan
alone, the cells treated with the combination showed
increased IBa, providing further evidence for stabiliza-
tion of NF-B under this condition.
Previous studies have shown that the tumor suppres-
sor gene CDKN1B encodes for a 27-kDa cyclin-depen-
dent kinase inhibitory protein, p27Kip1, which inhibits
cell proliferation and motility [19]. Our initial screening
studies (data not shown) have shown that AT/RT cells
also down regulate p27Kip1 in response to irinotecan.
Sorafenib, however, did not have this effect and the
irinotecan sorafenib combination did not lead to addi-
tional loss of p27Kip1 (Figure 5B).
Discussion
Currently, the prognosis for children with AT/RT is very
poor. Occasional anecdotal reports of successful treat-
ment are noted; but optimal therapy or even effective
therapy has not been achieved in most cases. The che-
motherapeutic agents classically used are cyclophospha-
mide, cisplatin, etoposide, vincristine, carboplatin and
ifosfamide [1]. The setback is that tumors seem to be
responsive initially but develop resistance [20]. However,
recent evidence suggests that improved survival can be
a c h i e v e dw i t ht h eu s eo fm o r ea g g r e s s i v et r e a t m e n t
approaches, including dose-intense chemotherapy and
adjuvant radiation therapy [21-23]. It has also been
shown that radiotherapy is crucial to improve the survi-
val rate of children with AT/RT [24,25]. Chi and collea-
gues have described an innovative treatment approach
consisting of an aggressive multimodality approach [26].
This protocol is the first prospective investigation con-
sisting of surgery, radiation therapy combined with
multi-agent systemic and IT chemotherapy and has
resulted in a significant improvement in time to pro-
gression and overall survival of AT/RT patients. In gen-
eral, the striking potential for long-term consequences
of treatments that include radiation in these very young
children necessitates trials with new therapeutics and
treatment regimens.
Figure 3 Irinotecan inhibits the in vitro growth of AT/RT cells. Triplicate cultures of AT/RT cell lines were cultured in the presence of
increasing concentrations of irinotecan. Following four days in culture, cell growth inhibition was measured by Alamar blue assay. Percentage of
cell survival was calculated by comparison of treated cells to control cells. Similar results were obtained in five separate experiments. IC50 values
obtained from these data are given in Table 2.
Table 3 Combination indices in drug combination studies
of irinotecan and the multi-kinase inhibitors sorafenib
and sunitinib
Inhibitor, CI BT 12 BT 16 KCCF1
Sorafenib 0.7 0.8 0.9
Sunitinib 0.9 0.3 0.4
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survival signals in rhabdoid tumors has been investi-
gated by a number of laboratories. In addition to the
effects of IGF-I described previously [27], our studies
have shown the expression of significant quantities of
VEGF and PDGF by all three cell lines (Table 1). Based
on this, we have explored the effects of two multi-kinase
inhibitors that have been shown to inhibit growth sti-
mulatory pathways mediated by the receptors of these
cytokines. Sorafenib and sunitinib are two oral multi-
targeted receptor-tyrosine kinase inhibitors that are cur-
rently in clinical trials for various malignancies.
Figure 4 The multi-kinase inhibitor sorafenib induces alterations in cellular signaling and apoptosis regulators in AT/RT cells in
response to conditioned medium. Addition of autologous conditioned medium to briefly serum starved cells provides an avenue to evaluate
the potential responses that may occur during autocrine/paracrine growth stimulation. In the presence of sorafenib (S), the conditioned medium
induced reduced phosphorylation of Erk1/2 (BT12, KCCF1), Akt1/2 (BT12), c-Raf (BT12), Stat3 (BT12, KCCF1) compared to DMSO (D) control. Under
these conditions, an increase in phosphorylation of c-Raf was noted in KCCF1 cells. However, the pro-survival protein Mcl-1 was suppressed by
sorafenib in all three cell lines (A). Compared to basal medium (BM), conditioned medium (CM) induced phosphorylation of signaling regulators,
such as Erk (B). The data shown are typical of three separate experiments.
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activity of c-Raf, b-Raf, vascular endothelial growth fac-
tor receptor family (VEGFR-2 and VEGFR-3), platelet-
derived growth factor receptor family (PDGFR-b )a n d
stem cell factor receptor (c-Kit). Sunitinib is a multitar-
geted inhibitor of VEGFR, PDGFR-a and -b, c-Kit and
Flt-3. These two agents offer broad anti-tumor efficacy
through their ability to directly and indirectly inhibit
Figure 5 Cytoplasmic NF-B levels are lowered by irinotecan but sorafenib reduces this effect. BT12 cells were incubated with sorafenib
or vehicle for 30 minutes followed by treatment with irinotecan for an additional 2 hours. For indirect immunofluorescence (A), cells were fixed
and stained with antibodies to NF-B followed by fluorescent labeled secondary antibodies. Concurrent DAPI stain was used to localize the
nuclei (lower panel). Slides were visualized using a fluorescent microscope and random fields were photographed. The cytoplasmic staining seen
in untreated and sorafenib treated cells was significantly reduced following treatment with irinotecan. However, the addition of sorafenib
enabled the cells to maintain cytoplasmic staining in the presence of irinotecan. For Western blot analysis (B), cytoplasmic proteins were
analyzed using antibodies against NFB p65 and p50, phospho-NFB p65, IBa and p27Kip1. In the presence of irinotecan, there was a loss of
cytoplasmic NF-Bp65, but in the presence of sorafenib, this loss was greatly reduced, corresponding to a decrease in phosphorylation of
NF-Bp65. In addition, compared to treatment with sorafenib or irinotecan alone, there was increased expression of IBa following treatment
with sorafenib and irinotecan. Lastly, following treatment with irinotecan and sorafenib irinotecan combination, there was decreased expression
of p27Kip1 compared to sorafenib treatment alone.
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tumor growth, survival, and angiogenesis [28]. It has
been shown in that the antiproliferative effect of sorafe-
nib is mediated through its effect on the MAP kinase
pathway (i.e., reduced Erk1/2 phosphorylation) [29]. Our
studies have shown a decrease in activated Erk1/2 in
two of the three cell lines (Figure 4A). In addition, we
have found a decrease in the anti-apoptotic protein
Mcl-1 in all three cell lines. Interestingly, the down reg-
ulation of Mcl-1 by sorafenib has been shown previously
in other tumor models [30]. Mcl-1 has also been impli-
cated in the generation of resistance to chemotherapeu-
tic agents [31]. Though we have shown significant
alterations in the activity of key signaling molecules in
AT/RT cells, the contribution of off-target effects by
sorafenib cannot be ruled out and awaits further analysis
in biological correlative studies in xenografts and in
future clinical trials of this agent.
Recently, sorafenib has been shown to inhibit prolifera-
tion and induce apoptosis in two medulloblastoma cell
lines (Daoy and D283) and a primary culture (VC312) of
human medulloblastoma at inhibitory concentrations very
similar to that we have observed against AT/RT cells (IC50
approximately 2.5 µM) [32]. In vivo activity of sorafenib
against medulloblastoma cells has also been demonstrated
in a mouse xenograft model [32]. Sunitinib has been
shown to induce apoptosis and growth arrest in medullo-
blastoma cells by inhibiting Stat3 and Akt signaling path-
ways [33]. In pre-clinical testing studies, Maris and co-
workers have observed activity of sunitinib against rhab-
doid tumor xenografts [34]. These findings support the
potential of sorafenib and sunitinib as effective treatments
in AT/RT. However, as a way to increase treatment effi-
cacy and to reduce potential adverse effects of these
agents, we explored additional drug combination studies.
Irinotecan has been shown to have the ability to cross
the blood-brain barrier and, in preclinical investigations,
has demonstrated cytotoxic activity against central ner-
vous system tumor xenografts [35]. Recently, a Phase I
trial of irinotecan by Pediatric Oncology Group (POG)
was performed in children with refractory solid tumors
where stable disease (4-20 cycles) was observed in seven
patients with a variety of malignancies, including a patient
with CNS AT/RT [36]. In recurrent malignant gliomas,
combination therapy with bevacizumab and irinotecan has
been shown to prolong progression-free survival in com-
parison with historical controls [37,38]. Our studies have
also shown the ability of irinotecan to inhibit the growth
of AT/RT cells and significant synergy in drug combina-
tions involving irinotecan with either sorafenib or sunitinib
(Table 3). In previous trials, despite the initial response to
therapy, most patients treated with irinotecan developed
resistance and showed tumor progression [39]. In the col-
orectal cancer model, treatment with irinotecan has been
shown to lead to the activation of NF-B. [40]. As such,
the activation of the NF-B pathway constitutes a poten-
tial mechanism of inducible resistance by malignant cells
exposed to irinotecan [41]. NF-Bi n t e r f e r e sw i t ht h e
effect of most anti-cancer drugs through induction of anti-
apoptotic genes. Targeting NF-B is therefore expected to
potentiate conventional treatments in adjuvant strategies.
In addition, recent studies have shown that the adminis-
tration of siRNA directed against the p65 subunit of NF-
B can effectively enhance in vitro and in vivo sensitivity
to chemotherapeutic agents [42]. Thus, reducing NF-B-
mediated activation may help prevent resistance poten-
tially generated upon exposure to irinotecan. This has
been confirmed in studies where a pharmacological inhibi-
tor of the IKK2 kinase (AS602868, Serono International
SA, Geneva, Switzerland) which blocks NF-B activation
has been found to enhance the action of irinotecan meta-
bolite [43]. We have explored the possibility of decreased
NF-B activation as a potential mechanism in the
enhanced cytotoxicity of irinotecan in the presence of sor-
afenib. Our studies have provided evidence for irinotecan
mediated loss of cytoplasmic NF-B in AT/RT cells. How-
ever, the presence of sorafenib appears to retain NF-Bi n
the cytoplasm as shown by Western blot analysis and
indirect immunofluoresence studies. Interestingly, in Alz-
heimer’s disease research, a similar observation was noted
where the chronic treatment with sorafenib inhibited
c-Raf and NF-B in the brains of the aged APPswe mice
[44].
Conclusions
In this study, we have shown that the AT/RT cell lines
produce a number of cytokines and the multi-kinase inhi-
bitors sorafenib and sunitinib induce cell growth inhibition
in these cell lines. The effect of sorafenib resulted in the
loss of active signaling molecules Erk1/2 in response to
conditioned media in two of the three cell lines. We also
show that sorafenib inhibits a multitude of signaling mole-
cules in a cell line dependent manner but the loss of the
pro-survival protein Mcl-1 was noted in all cell lines stu-
died. We have also shown the synergistic activity of these
agents with the topoisomerase I inhibitor irinotecan and
provided evidence for the inhibition of NF-B activation
as one potential advantage in this drug combination. We
believe that the data presented here provide the basis for
further studies to evaluate the effects of multi-tyrosine
kinases in xenograft studies and subsequently for the for-
mulation of clinical studies in patients with AT/RT.
Methods
Cell lines and cell culture
BT12 and BT16 cell lines were a gift from Drs. Peter
Houghton and Jaclyn Biegel (St. Jude Children’s Research
Hospital, Memphis, TN, USA). These cell lines have been
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six-week-old female; BT16 from a two-year-old male).
KCCF1 was established in our laboratory with cells
obtained from the Cerebral Spinal Fluid (CSF) of a two-
month-old male infant with AT/RT. Characterization of
this cell line has been described previously [9].
Cells were cultured in Opti-MEM medium (Gibco, Invi-
trogen Corporation, Burlington, Ontario, Canada) supple-
mented with 5% fetal bovine serum (Gibco), 100 units/ml
each of penicillin and streptomycin (Gibco). Confluent
cells were trypsinized with 0.25% Trypsin-EDTA in Ca2+
and Mg2+ free balanced salt solution (Gibco) every three
to five days. All cell cultures were maintained at 37 °C in a
humidified atmosphere with 5% CO2.
Multiplex cytokine assay
Cells (2 × 10
6) in 2 ml of medium were grown for
48 hours and culture supernatants were analyzed for cyto-
kine levels by multiplex technology as described previously
[45]. Briefly, culture supernatants were diluted 1:4 in sam-
ple diluent buffer and mixed with beads containing cap-
ture antibodies. After incubation and washing steps, beads
were mixed and incubated with biotin conjugated detec-
tion antibodies. Following the detection antibody incuba-
tion, each well was filter-washed and incubated in the dark
with streptavidin-phycoerythrin (PE) conjugate. The plates
were washed and the contents of each well were re-
suspended in assay buffer. The plates were read in a Lumi-
nex100™ multiplex assay detection system (Luminex
Corp., Austin, Texas, USA) and quantitatively analyzed
using STarStation 2.0 software (Applied Cytometry, Shef-
field, United Kingdom). In this study, a panel containing
the following 65 human cytokines and chemokines was
used: EGF, Eotaxin, FGF(basic), Flt-3, Ligand, Fractalkine,
G-CSF, GM-CSF, GRO, IFN alpha2, IFN gamma, IL-1al-
pha, IL-1beta, IL-1Ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-
8, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17,
IP-10, MCP-1, MCP-3, MDC, MIP-1alpha, MIP-1beta,
PDGF-AA, PDGF-AB/BB, RANTES, CD40L, SDF-1, sIL-
2R alpha, TGF alpha, TNFbeta, MCP-2, MCP-4, ENA-78,
BCA-1, I-309, IL-16, MIP-1delta, TARC, 6Ckine, Eotaxin-
2, Eotaxin-3, CTACK, IL-23, LIF, TPO, TRAIL, SCF,
TSLIP, VEGF, IL-20, IL-21, IL-28A and IL-33.
Antineoplasic agents
Sorafenib, sunitinib, irinotecan and SN-38 were obtained
from ChemieTek (Indianapolis, Indiana, USA) and the
Oncology pharmacy at the Alberta Children’s Hospital.
These agents were dissolved in DMSO (Sigma-Aldrich,
Oakville, Ontario, Canada) to a final concentration of 10
mM and stored in aliquots at -20°C. At the time of
study, agents were then appropriately diluted in culture
medium.
Cell growth inhibition assay
AT/RT cells were detached from the flask by trypsiniza-
tion and plated in 96 well plates at a concentration of 1 ×
10
3 to 5 × 10
3 cells per well. Increasing concentrations of
study agents were added to these wells to a final volume of
200 µl per well. Corresponding dilutions of the vehicle
DMSO was used as control. After four days in culture, cell
survival was quantified by Alamar Blue Assay (Medicorp,
Montreal, Quebec, Canada), according to manufacturer’s
protocol. Briefly, cells were incubated with 2.5% Alamar
blue (which incorporates a proprietary redox indicator
that changes color in response to metabolic activity) for 2
to 24 hours, and the absorbency at 570-620 nm was mea-
sured (Opsys MR Plate Reader, Dynex Technologies,
Chantilly, Virginia, USA). Percent cell survival was calcu-
lated by:% Survival = (Abs 570-620 test well/Abs 570-620
Control) × 100.
From these values, inhibitory concentrations inducing
50% cell death (IC50) compared to DMSO wells were cal-
culated. For drug combination studies irinotecan at IC25
concentration was added to cultures containing increasing
concentrations of sorafenib or sunitinib. IC50 values were
then calculated for these agents alone or in combination
with irinotecan and used to derive Combination Index
(CI) values as described previously [16]. A CI of less than
1 indicates synergy between the two agents under the
experimental conditions used.
Western Blot Analysis
In order to determine the expression of cellular targets of
sorafenib and sunitinib in AT/RT cell lines, cells were
grown to confluence in six well culture plates (Nunc,
Rochester, New York, USA) over a 24 hour period. The
media was removed and cells were washed with ice cold
PBS and lysed in buffer containing 50 mM Tris, 5 mM
EDTA, 0.1% SDS, 1% Triton X-100, 0.5% sodium deoxy-
cholate with phosphatase and protease inhibitors (Sigma).
Protein content of the lysates was measured by BCA Pro-
tein Assay Kit (Pierce, Rockford, Illinois, USA). Proteins
(30µg/sample) were separated on an 8% polyacrylamide
gel electrophoresis and transferred onto nitrocellulose
membranes (Bio-Rad, Mississauga, Ontario, Canada). The
membranes were blocked for two hours at 4°C with 5%
skim milk powder in PBS containing 0.1% Tween-20
(Sigma). The blots were incubated with primary antibodies
to c-Kit (1:1000, Santa Cruz Biotechnology, Santa Cruz,
California, USA), PDGFR-b (1:1000, Santa Cruz), VEGFR2
(1:1000, Millipore, Billerica, Massachusetts, USA), Flt-3
(1:1000, Santa Cruz), c-Raf (1:1000, Cell Signaling Tech-
nology, Danvers, Massachusetts, USA), p-38a (1:1000,
Santa Cruz) and b-actin (1: 10000, Sigma). After incuba-
tion overnight at 4°C, membranes were washed and
probed with appropriate secondary antibodies conjugated
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Page 9 of 11to horseradish peroxidase (HRPO) (Sigma), followed by a
luminal based substrate (Mandel, Guelph, Ontario,
Canada) and developed by exposure to x-ray film (Fisher
Scientific, Ottawa, Ontario, Canada). For intracellular sig-
naling studies, cells were grown to confluence in six well
culture plates and culture supernatant (spent medium)
was removed, filtered and stored at 4°C and fresh serum
free medium containing 10 μM sorafenib or vehicle
(DMSO) control was added to the cells. After an addi-
tional two hours in culture the spent medium was added
(10% v/v). Following further 30 min in the incubator, cells
were lysed as described above and analyzed by Western
blot using primary antibodies to Erk1/2 (1:1000, Cell Sig-
naling), phospho-Erk1/2 (1:2000, R & D Systems, Minnea-
polis, Minnesota, USA), Akt1/2 (1:1000, Santa Cruz),
phospho-Akt1/2 (1:1000, Santa Cruz), c-Raf (1:1000, Cell
Signaling Technology), phospho-c-Raf (1:1000, Cell Signal-
ing), Stat3 (1:1000, Cell Signaling), phospho-Stat3 (1:1000,
Cell Signaling), Mcl-1 (1:1000, Santa Cruz) and b-actin.
For the analysis of cytoplasmic NF-B, phospho-NF-B
and IBa,c e l l sw e r eg r o w ni nc u l t u r ef o r2d a y s ,a f t e r
which the media was removed and replaced with serum
free media. The cells were then treated with sorafenib (10
µM) or DMSO control for 30 minutes, then irinotecan (10
µM) for an additional 2 hours. Cell lysates were then ana-
lyzed by using primary antibodies to NF-Bp65 (1:1000,
Santa Cruz), phospho-NFBp65 (1:1000, Cell Signaling),
NF-Bp50 (1:2000, Millipore), IBa (1:1000, Cell Signal-
ing) and b-actin. For analysis of p27Kip1 expression, cells
were treated with either sorafenib (1 µM) or irinotecan
(1 µM) or both for 48 hours. Expression of p27Kip1 was
determined using anti-p27Kip1 (1:1000, Cell Signaling).
Immunofluorescence analysis of cytoplasmic NF-B
BT12 cells were cultured in six well plates (2 × 10
6/well)
overnight and treated with (1) vehicle alone, (2) sorafenib
(10 μM), (3) irinotecan (10 μM) and (4) sorafenib for
30 minutes followed by treatment with irinotecan for an
additional 2 hours. Indirect immunofluoresence studies
were carried out as described previously [46]. Briefly, after
various treatments, cells were washed with cold PBS, fixed
and incubated with antibodies to NF-B( S a n t aC r u z )
for 1 hour, followed by fluorescent labeled secondary anti-
bodies (30 min). Concurrent DAPI staining was performed
to locate nuclei in each slide. Slides were visualized under
a fluorescent microscope and random fields were
photographed.
Acknowledgements
These studies were funded in part by the Alberta Children’s Hospital
Foundation (ACHF), Kids Cancer Care Foundation of Alberta (KCCFA) and the
Brain Tumor Foundation of Canada. AJ holds a Canadian Institutes for Health
Research (CIHR) Training Program in Genetics, Child Development and
Health Graduate Studentship awarded by the Alberta Children’s Hospital
Research Institute (ACHRI) and a McCarthy Tetrault Graduate Studentship
awarded by ACHF.
Author details
1Laboratory for Pre-clinical and Drug Discovery Studies, Pediatric Oncology
Experimental Therapeutics Investigators Consortium (POETIC) and Division of
Pediatric Oncology, Alberta Children’s Hospital, 2888 Shaganappi Trail NW,
Calgary, T3B 6A8, Canada.
2Departments of Biochemistry and Molecular
Biology and Oncology, University of Calgary, 3330 Hospital Drive NW,
Calgary, T2N 4N1, Canada.
Authors’ contributions
AJ planned and performed drug combination studies and Western blot
analysis. DB planned and performed cytotoxicity studies. PB and KR
facilitated the indirect immunofluorescence analysis and helped to write the
manuscript. AN planned and supervised the studies and wrote the
manuscript. All authors have read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 30 April 2010 Accepted: 29 December 2011
Published: 29 December 2011
References
1. Bikowska B, Grajkowska W, Jozwiak J: Atypical teratoid/rhabdoid tumor:
short clinical description and insight into possible mechanism of the
disease. Eur J Neurol 2011, 18:813-818.
2. Biegel JA: Molecular genetics of atypical teratoid/rhabdoid tumor.
Neurosurg Focus 2006, 20:E11.
3. Dufour C, Beaugrand A, Le Deley MC, Bourdeaut F, André N, Leblond P,
Bertozzi AI, Frappaz D, Rialland X, Fouyssac F, Edan C, Grill J, Quidot M,
Varlet P: Clinicopathologic prognostic factors in childhood atypical
teratoid and rhabdoid tumor of the central nervous system: A
multicenter study. Cancer 2011, Electronically published ahead of print.
4. Bouvier C, De Paula AM, Fernandez C, Quilichini B, Scavarda D, Gentet JC,
Figarella-Branger D: Atypical teratoid/rhabdoid tumor: 7-year event-free
survival with gross total resection and radiotherapy in a 7-year-old boy.
Childs Nerv Syst 2008, 24:143-147.
5. Guidi CJ, Sands AT, Zambrowicz BP, Turner TK, Demers DA, Webster W,
Smith TW, Imbalzano AN, Jones SN: Disruption of Ini1 leads to peri-
implantation lethality and tumorigenesis in mice. Mol Cell Biol 2001,
21:3598-3603.
6. Foster KS, McCrary WJ, Ross JS, Wright CF: Members of the hSWI/SNF
chromatin remodeling complex associate with and are phosphorylated
by protein kinase B/Akt. Oncogene 2006, 25:4605-4612.
7. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Izumi T, Ohta S, Taguchi T,
Suita S, Tsuneyoshi M: Highly aggressive behavior of malignant rhabdoid
tumor: a special reference to SMARCB1/INI1 gene alterations using
molecular genetic analysis including quantitative real-time PCR. J Cancer
Res Clin Oncol 2007, 133:817-824.
8. Albanese P, Belin MF, Delattre O: The tumor suppressor hSNF5/INI1
controls the differentiation potential of malignant rhabdoid cells. Eur J
Cancer 2006, 42:2326-2334.
9. Narendran A, Coppes L, Jayanthan A, Coppes M, Teja B, Bernoux D,
George D, Strother D: Establishment of atypical-teratoid/rhabdoid tumor
(AT/RT) cell cultures from disseminated CSF cells: a model to elucidate
biology and potential targeted therapeutics. J Neurooncol 2008,
90:171-180.
10. D’cunja J, Shalaby T, Rivera P, von Büren A, Patti R, Heppner FL, Arcaro A,
Rorke-Adams LB, Phillips PC, Grotzer MA: Antisense treatment of IGF-IR
induces apoptosis and enhances chemosensitivity in central nervous
system atypical teratoid/rhabdoid tumours cells. Eur J Cancer 2007,
43:1581-1589.
11. Arcaro A, Doepfner KT, Boller D, Guerreiro AS, Shalaby T, Jackson SP,
Schoenwaelder SM, Delattre O, Grotzer MA, Fischer B: Novel role for insulin
as an autocrine growth factor for malignant brain tumour cells. Biochem
J 2007, 406:57-66.
12. Petrelli A, Giordano S: From single- to multi-target drugs in cancer
therapy: when aspecificity becomes an advantage. Curr Med Chem 2008,
15:422-432.
Jayanthan et al. Cancer Cell International 2011, 11:44
http://www.cancerci.com/content/11/1/44
Page 10 of 1113. Papaetis GS, Syrigos KN: Sunitinib: a multitargeted receptor tyrosine
kinase inhibitor in the era of molecular cancer therapies. BioDrugs 2009,
23:377-389.
14. Hartmann JT, Haap M, Kopp HG, Lipp HP: Tyrosine Kinase Inhibitors - A
Review on Pharmacology, Metabolism and Side Effects. Curr Drug Metab
2009, 10:470-481.
15. Feun L, Savaraj N: Topoisomerase I inhibitors for the treatment of brain
tumors. Expert Rev Anticancer Ther 2008, 8:707-716.
16. Chou TC: Drug combination studies and their synergy quantification
using the Chou-Talalay method. Cancer Res 2010, 70:440-446.
17. Nakanishi C, Toi M: Nuclear factor-kappaB inhibitors as sensitizers to
anticancer drugs. Nat Rev Cancer 2005, 5:297-309.
18. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V,
Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF:
Pharmacological targeting of NF-kappaB potentiates the effect of the
topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008,
98:335-344.
19. Schiappacassi M, Lovat F, Canzonieri V, Belletti B, Berton S, Di Stefano D,
Vecchione A, Colombatti A, Baldassarre G: p27Kip1 expression inhibits
glioblastoma growth, invasion and tumor-induced neoangiogenesis. Mol
Cancer Ther 2008, 7:1164-1175.
20. Strother D: Atypical teratoid rhabdoid tumors of childhood: diagnosis,
treatment and challenges. Expert Rev Anticancer Ther 2005, 5:907-915.
21. Tekautz TM, Fuller CE, Blaney S, Fouladi M, Broniscer A, Merchant TE,
Krasin M, Dalton J, Hale G, Kun LE, Wallace D, Gilbertson RJ, Gajjar A:
Atypical teratoid/rhabdoid tumors (ATRT): improved survival in children
3 years of age and older with radiation therapy and high-dose alkylator-
based chemotherapy. J Clin Oncol 2005, 23:1491-1499.
22. Shih CS, Hale GA, Gronewold L, Tong X, Laningham FH, Gilger EA,
Srivastava DK, Kun LE, Gajjar A, Fouladi M: High-dose chemotherapy with
autologous stem cell rescue for children with recurrent malignant brain
tumors. Cancer 2008, 112:1345-1353.
23. Gidwani P, Levy A, Goodrich J, Weidenheim K, Kolb EA: Successful
outcome with tandem myeloablative chemotherapy and autologous
peripheral blood stem cell transplants in a patient with atypical
teratoid/rhabdoid tumor of the central nervous system. J Neurooncol
2008, 88:211-215.
24. Squire SE, Chan MD, Marcus KJ: Atypical teratoid/rhabdoid tumor: the
controversy behind radiation therapy. J Neurooncol 2007, 81:97-111.
25. Chen YW, Wong TT, Ho DM, Huang PI, Chang KP, Shiau CY, Yen SH: Impact
of radiotherapy for pediatric CNS atypical teratoid/rhabdoid tumor
(single institute experience). Int J Radiat Oncol Biol Phys 2006,
64:1038-1043.
26. Chi SN, Zimmerman MA, Yao X, Cohen KJ, Burger P, Biegel JA, Rorke-
Adams LB, Fisher MJ, Janss A, Mazewski C, Goldman S, Manley PE,
Bowers DC, Bendel A, Rubin J, Turner CD, Marcus KJ, Goumnerova L,
Ullrich NJ, Kieran MW: Intensive multimodality treatment for children
with newly diagnosed CNS atypical teratoid rhabdoid tumor. J Clin Oncol
2009, 27:385-389.
27. Ogino S, Kubo S, Abdul-Karim FW, Cohen ML: Comparative
immunohistochemical study of insulin-like growth factor II and insulin-
like growth factor receptor type 1 in pediatric brain tumors. Pediatr Dev
Pathol 2001, 4:23-31.
28. Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C,
Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the
treatment of advanced non-small cell lung cancer. Oncologist 2007,
12:191-200.
29. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C,
Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D,
Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R,
Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits
broad spectrum oral antitumor activity and targets the RAF/MEK/ERK
pathway and receptor tyrosine kinases involved in tumor progression
and angiogenesis. Cancer Res 2004, 64:7099-7109.
30. Yu C, Bruzek LM, Meng XW, Gores GJ, Carter CA, Kaufmann SH, Adjei AA:
The role of Mcl-1 downregulation in the proapoptotic activity of the
multikinase inhibitor BAY 43-9006. Oncogene 2005, 24:6861-6869.
31. Warr MR, Shore GC: Unique biology of Mcl-1: therapeutic opportunities in
cancer. Curr Mol Med 2008, 8:138-147.
32. Yang F, Van Meter TE, Buettner R, Hedvat M, Liang W, Kowolik CM,
Mepani N, Mirosevich J, Nam S, Chen MY, Tye G, Kirschbaum M, Jove R:
Sorafenib inhibits signal transducer and activator of transcription 3
signaling associated with growth arrest and apoptosis of
medulloblastomas. Mol Cancer Ther 2008, 7:3519-3526.
33. Yang F, Jove V, Xin H, Hedvat M, Van Meter TE, Yu H: Sunitinib induces
apoptosis and growth arrest of medulloblastoma tumor cells by
inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010,
8:35-45.
34. Maris JM, Courtright J, Houghton PJ, Morton CL, Kolb EA, Lock R,
Tajbakhsh M, Reynolds CP, Keir ST, Wu J, Smith MA: Initial testing (stage 1)
of sunitinib by the pediatric preclinical testing program. Pediatr Blood
Cancer 2008, 51:42-48.
35. Houghton PJ, Cheshire PJ, Hallman JD, Lutz L, Friedman HS, Danks MK,
Houghton JA: Efficacy of topoisomerase I inhibitors, topotecan and
irinotecan, administered at low dose levels in protracted schedules to
mice bearing xenografts of human tumors. Cancer Chemother Pharmacol
1995, 36:393-403.
36. Blaney S, Berg SL, Pratt C, Weitman S, Sullivan J, Luchtman-Jones L,
Bernstein M: A phase I study of irinotecan in pediatric patients: a
pediatric oncology group study. Clin Cancer Res 2001, 7:32-37.
37. Norden AD, Drappatz J, Wen PY: Novel anti-angiogenic therapies for
malignant gliomas. Lancet Neurol 2008, 7:1152-1160.
38. Vredenburgh JJ, Desjardins A, Reardon DA, Friedman HS: Experience with
irinotecan for the treatment of malignant glioma. Neuro Oncol 2009,
11:80-91.
39. Calvo E, Cortes J, Rodriguez J, Fernandez-Hidalgo O, Rebollo J, Martin-
Algarra S, Garcia-Foncillas J, Martinez-Monge R, de Irala J, Brugarolos A:
Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination
chemotherapy in advanced colorectal carcinoma: a Phase II study. Clin
Colorectal Cancer 2002, 2:104-110.
40. Xu Y, Villalona-Calero MA: Irinotecan: mechanisms of tumor resistance
and novel strategies for modulating its activity. Ann Oncol 2002,
13:1841-1851.
41. Wang CY, Mayo MW, Korneluk RG, Goeddel DV, Baldwin AS Jr: NF-kappaB
antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to
suppress caspase-8 activation. Science 1998, 281:1680-1683.
42. Guo J, Verma UN, Gaynor RB, Frenkel EP, Becerra CR: Enhanced
chemosensitivity to irinotecan by RNA interference-mediated down-
regulation of the nuclear factor-kappaB p65 subunit. Clin Cancer Res
2004, 10:3333-3341.
43. Lagadec P, Griessinger E, Nawrot MP, Fenouille N, Colosetti P, Imbert V,
Mari M, Hofman P, Czerucka D, Rousseau D, Berard E, Dreano M, Peyron JF:
Pharmacological targeting of NF-kappaB potentiates the effect of the
topoisomerase inhibitor CPT-11 on colon cancer cells. Br J Cancer 2008,
98:335-344.
44. Echeverria V, Burgess S, Gamble-George J, Zeitlin R, Lin X, Cao C,
Arendash GW: Sorafenib inhibits nuclear factor kappa B, decreases
inducible nitric oxide synthase and cyclooxygenase-2 expression, and
restores working memory in APPswe mice. Neuroscience 2009,
162:1220-1231.
45. Levina V, Su Y, Nolen B, Liu X, Gordin Y, Lee M, Lokshin A, Gorelik E:
Chemotherapeutic drugs and human tumor cells cytokine network. Int J
Cancer 2008, 123:2031-2040.
46. Han X, Feng X, Rattner JB, Smith H, Bose P, Suzuki K, Soliman MA, Scott MS,
Burke BE, Riabowol K: Tethering of the ING1 protein to Lamin A is
required for ING1 function in apoptosis. Nat Cell Biol 2008, 10:1333-1340.
doi:10.1186/1475-2867-11-44
Cite this article as: Jayanthan et al.: Multi-tyrosine kinase inhibitors in
preclinical studies for pediatric CNS AT/RT: Evidence for synergy with
Topoisomerase-I inhibition. Cancer Cell International 2011 11:44.
Jayanthan et al. Cancer Cell International 2011, 11:44
http://www.cancerci.com/content/11/1/44
Page 11 of 11